Finland based Biohit healthcare establishes a Joint Venture in China with AnnAnhui Wisdom-Win Investment Co., Ltd.

Finland based healthcare company Biohit Oyj will be setting up a Joint Venture in China with Anhui Wisdom-Win Investment Co., Ltd. The Joint Venture company will be named Biohit Biotech (Hefei) Co., Ltd., located in the city of Hefei in Anhui province, China.

 The objective of the Joint Venture is to manufacture and sell high quality GastroPanel kits to the Chinese market area. Apart from China, recently Biohit has also collaborated for sales and distribution in Gemany with IBL International.

Amgen and Astellas enter into a strategic Alliance for Japanese Market

There are two parts of the strategic alliance

1. The first element of the alliance is a long-term collaboration between the two companies that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline medicines. (Table 1)

Amgen and Zhejian Beta Pharma form a Joint Venture for commercialization of Amgen's Vectibix in China

Amgen and Zhejiang Beta Pharma Co., Ltd. today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix^® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.

Guizhou Factorr, a subsidiary of Hua Han Bio-Pharmaceutical Holdings Ltd. Enters into a Joint Venture with National Vaccine & Serum Institute (NVSI)

As per the terms of the Joint Venture, NVSI and Guizhou Factorr will jointly establish a new company in Guizhou Province. NVSI would contribute to 51% and Guizhou Factorr would contribute to 49% of the registered capital of the New Company.  

After the New Company is established, NVSI and the New Company will enter into agreements in relation to the transfer of technical know-how of three medical products, including placenta pills, placenta blood albumin injection and placenta tissue fluid injection. NVSI will transfer the relevant technical know-how to the New Company according to the fair value assessed by an asset valuation firm. 

NVSI and Guizhou Factorr confirmed that the fair value of know-how of placenta pills, placenta blood albumin injection and placenta tissue fluid injection are RMB12,000,000 (equivalent to HK$15,074,400), RMB5,000,000 (equivalent to HK$6,281,000) and RMB5,000,000 (equivalent to HK$6,281,000) respectively. 

Domain Associates a US based Venture capital firm and Elite consulting partner to bring new healthcare products to China

Domain Associates, a US venture capital firm focused on life science, has set up a partnership with Elite Consulting, a consultant service for China's drug and medical device industry. They will establish a new entity called Domain Elite that will aim at bringing new healthcare products to China. Domain Elite will provide Western companies with financing, regulatory advice and marketing support. The initial products will be drawn from Domain's life science investments.

China Grand Pharmaceuticals enter into JV with HuangShi Feiyun

HuangShi Feiyun and China Grand Pharmaceutical and Healthcare Holdings Ltd. have entered into a joint venture which will be established in Huangshi, the PRC. The purpose of establishing the joint venture company is to set up a national naturally-sourced medicine research and development and manufacturing base in Huangshi, the PRC. The joint venture company will be owned beneficially as to 60% by Grand Pharm and as to the balance of 40% by HuangShi Feiyun. Upon its establishment, the joint venture company will become a 60% owned subsidiary of the company. Pursuant to the terms of the JV agreement, the registered capital of the joint venture company will be RMB 125,000,000 (equivalent to approximately HKD 155,300,000 or $20m). RMB 75,000,000 (equivalent to approximately HKD 93,200,000 or $12m) will be contributed by Grand Pharm by way of cash and the balance of RMB 50,000,000 (equivalent to approximately HKD 62,100,000 ) will be contributed by HuangShi Feiyun as to RMB 30,000,000 (equivalent to approximately HKD 37,300,000) by way of injection of intangible assets in the joint venture company and as to RMB 20,000,000 (equivalent to approximately HKD 24,800,000) by way of cash.

GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries

GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases.

PharmaScience enters Korea with a Joint Venture with Korea Kolmar Holdings

Privately-held Canadian drugmaker Pharmascience and Korea Kolmar Holdings, based in Seoul, South Korea, have entered into a Joint Venture arrangement. Both companies would be equally contributing to the capital of the newly formed JV company. The JV (PharmaScience Korea) hopes to obtain required regulatory approvals from the Korea FDA so as to be able to initiate selling generic medicines in Korea by mid 2014.   The JV will initially target to sell CNS drugs.  The products will be manufactured by Pharmascience at its manufacturing facility in Montreal.

Korean Generic market is ranked 13th largest in the world.

Otsuka, Mitsui and Claris Life Science enter into a Joint Venture

Otsuka Holdings announced today that Otsuka Pharmaceutical Factory, Inc,(OPF)  a subsidiary of Otsuka Holdings, will establish a joint venture in India with Mitsui & Co., Ltd. and Claris Lifesciences Limited.

Ownership of  the Joint Venture

Otsuka, Mitsui and Claris reached an agreement that Otsuka and Mitsui will jointly acquire capital in a company specialized IV solutions business that will be newly established by Claris, one of the leading manufacturers and distributors of IV solutions and generic pharmaceuticals in India.  . The tentative name of the new entity would be "Claris Otsuka"and the equity ownership for each company will be; Otsuka: 60%, Mitsui: 20%, and Claris: 20%.

Valuation and Business of the Joint Venture

Claris will contribute to the Joint Venture company its business of Common Solutions, Anti-Infectives, Plasma Volume Expanders and Parenteral nutrition therapies. Two out of the five plants will be transferred to Claris Otsuka. The Joint Venutre company will also introduce OPF's speciality products in India and Emerging markets. The business transferred contributes 55 percent of Claris current revenues.

The business transferred has been valued at 1313 crores and Claris will receive INR 1050 crores or INR 10.5b from Otsuka and Mitsui (approximately 16 billion JPY or USD 200million) for the 80 percent stake in the JV.

Hetero and UAE based Neopharma enter into a Joint Venture

UAE based Neo pharma has set up a joint venture with Hyderabad-based Hetero Group. The JV company will be known as Nexgen Pharma and will  manufacture  and distribute medicines in the UAE..  In the the first phase of the collaboration Nexgen will be distributing 21 drugs from Hetero. As the registration process progresses   over the next 2 year, the product base will double to 50. By 2016, the JV would be distributing about 100 products.

This is the  second JV in the recent past for the Middle east region. The other JV announced recently was between Newbridge and UCB.